[1] [1] GUGLIESI F, COSCIA A, GRIFFANTE G, et al. Where do we stand after decades of studying human cytomegalovirus?［J］. Microorganisms, 2020, 8(5): 685.

[2] [2] GRIFFITHS P, BARANIAK I, REEVES M. The pathogenesis of human cytomegalovirus［J］. Journal of Pathology, 2015, 235(2): 288-297.

[3] [3] MANANDHAR T, HO G T, PUMP W C, et al. Battle between host immune cellular responses and HCMV immune evasion［J］. International Journal of Molecular Sciences, 2019, 20(15): 3626.

[4] [4] PLOTKIN S A, BOPPANA S B. Vaccination against the human cytomegalovirus［J］. Vaccine, 2019, 37(50): 7437-7442.

[5] [5] HAKKI M. Moving past ganciclovir and foscarnet: advances in CMV therapy［J］. Current Hematologic Malignancy Reports, 2020, 15(2): 90-102.

[6] [6] GERNA G, LILLERI D, BALDANTI F. An overview of letermovir: a cytomegalovirus prophylactic option［J］. Expert Opinion on Pharmacotherapy, 2019, 20(12): 1429-1438.

[7] [7] SANTOS BRAVO M, PLAULT N, SANCHEZ PALOMINO S, et al. Phenotype and genotype study of novel C480F maribavir-ganciclovir cross-resistance mutation detected in hematopoietic stem cell and solid organ transplant recipients［J］. Journal of Infectious Diseases, 2021, 224(6): 1024-1028.

[8] [8] MAERTENS J, CORDONNIER C, JAKSCH P, et al. Maribavir for preemptive treatment of cytomegalovirus reactivation［J］. New England Journal of Medicine, 2019, 381(12): 1136-1147.

[9] [9] ZHANG D H, WU K L, ZHANG X, et al. In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus［J］. Journal of Integrative Medicine, 2020, 18(2): 152-158.

[11] [11] COSTA R, WAGNER D E, DORYAB A, et al. A drug screen with approved compounds identifies amlexanox as a novel Wnt/beta-catenin activator inducing lung epithelial organoid formation［J］. British Journal Pharmacology, 2021, 178(19): 4026-4041.

[12] [12] YI L, LI Z, YUAN K, et al. Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells［J］. Journal of Virology, 2004, 78(20): 11334-11339.

[13] [13] MAVHANDU L G, CHENG H, BOR Y C, et al. Development of a pseudovirus assay and evaluation to screen natural products for inhibition of HIV-1 subtype C reverse transcriptase［J］. Journal of Ethnopharmacology, 2020, 258: 112931.

[14] [14] YAMAMOTO M, ICHINOHE T, WATANABE A, et al. The antimalarial compound atovaquone inhibits Zika and dengue virus infection by blocking E protein-mediated membrane fusion［J］. Viruses, 2020, 12(12): 1475.

[15] [15] NOGALES A, AVILA-PEREZ G, RANGEL-MORENO J, et al. A novel fluorescent and bioluminescent bireporter influenza A virus to evaluate viral infections［J］. Journal of Virology, 2019, 93(10): e00032-19.

[16] [16] ECKERT N, WRENSCH F, G?RTNER S, et al. Influenza A virus encoding secreted Gaussia luciferase as useful tool to analyze viral replication and its inhibition by antiviral compounds and cellular proteins［J］. PLoS One, 2014, 9(5): e97695.

[18] [18] LI L, GAO H, LOU K, et al. Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy Chinese subjects: a single-center, randomized, double-blind, placebo-controlled multiple-ascending-dose study［J］. Clinical and Translational Science, 2021, 14(5): 2017-2024.

[19] [19] EVERS D L, CHAO C F, WANG X, et al. Human cytomegalovirus-inhibitory flavonoids: studies on antiviral activity and mechanism of action［J］. Antiviral Research, 2005, 68(3): 124-134.

[20] [20] SHANG L, QU Z, SUN L, et al. Astragaloside IV inhibits adenovirus replication and apoptosis in A549 cells in vitro［J］. Journal of Pharmacy and Pharmacology, 2011, 63(5): 688-694.

[21] [21] LIU W, HE H, ZHENG S Y. Microfluidics in single-cell virology: technologies and applications［J］. Trends in Biotechnology, 2020, 38(12): 1360-1372.